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Abstract
Peroxisomal biogenesis is a complex process requiring the action of numerous peroxins. One central component of this machinery is
Pex14p, an intrinsic peroxisomal membrane protein probably involved in the docking of Pex5p, the receptor for PTS1-containing proteins
(peroxisomal targeting signal 1-containing proteins). In this work the membrane topology of mammalian Pex14p was studied. Using a
combination of protease protection assays and CNBr cleavage, we show that the first 130 amino acid residues of Pex14p are highly protected
from exogenously added proteases by the peroxisomal membrane itself. Data indicating that this domain is responsible for the strong
interaction of Pex14p with the organelle membrane are presented. All the other Pex14p amino acid residues are exposed to the cytosol. The
properties of recombinant human Pex14p were also characterised. Heterologous expressed Pex14p was found to be a homopolymer of
variable stoichiometry. Finally, in vitro binding assays indicate that homopolymerisation of Pex14p involves a domain comprising amino acid
residues 147–278 of this peroxin.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Peroxisomes are ubiquitous organelles of eukaryotic cells
involved in a variety of metabolic processes. In mammals,
examples of biochemical pathways requiring peroxisomal
enzymes are: h-oxidation of very long-chain fatty acids,
synthesis of cholesterol, ether phospholipids and bile acids
and the catabolism of phytanic acid and pipecolic acid
(reviewed in Ref. [1]). The importance of these organelles
to the cellular biochemistry is illustrated by the existence of
several human genetic diseases in which one or several
peroxisomal functions are missing. Many of these genetic
disorders (e.g., Zellweger syndrome, neonatal adrenoleuko-
dystrophy and infantile Refsum disease) arise from muta-
tions in genes involved in the biogenesis of the organelle
(reviewed in Refs. [2,3]). This observation has fuelled
intensive research on the genes and mechanisms regulating
the biogenesis of peroxisomes. Presently, more than 20
peroxins (proteins involved in the biogenesis of the perox-
isome) have been characterised (reviewed in Refs. [2,3]).
Peroxisomal matrix proteins are synthesised on cytosolic
ribosomes and posttranslationally imported into the organ-
elle [4]. Specific targeting of these proteins to the perox-
isome is accomplished by two receptors, Pex5p and Pex7p.
The vast majority of peroxisomal proteins use Pex5p as their
receptor [5–9]. These proteins possess the so-called PTS1, a
carboxy-terminal tripeptide with the sequence SKL (or a
derivative of this) ([10] and reviewed in Ref. [11]). A minor
fraction of peroxisomal matrix proteins has a different
targeting signal (PTS2)—a degenerated nonapeptide present
at the N terminus of the protein with the sequence (R/K)(L/
V/I)X5(H/Q)(L/A) (reviewed in Refs. [11,12]). PTS2-con-
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taining proteins are targeted to the peroxisome by Pex7p
[13,14].
It is generally accepted that proteins en route to the
peroxisome interact with the cognate receptor while still in
the cytosol, an idea supported by the observation that both
Pex5p and Pex7p are largely (soluble) cytosolic proteins (re-
viewed in Ref. [11]). Thus, this model also implies the
existence of docking proteins at the peroxisomal membrane
capable of recognising these receptor–cargo complexes.
From the several membrane peroxins presently known,
Pex14p seems to be the best candidate to perform this
function.
In addition to Pex5p, several other peroxins interact with
Pex14p. In mammals, the interactions of Pex14p with itself
[15] and with Pex13p [9,16] and Pex19p [17] are well
documented. In lower eukaryotes the list of Pex14p-inter-
acting peroxins also includes Pex3p [18], Pex7p [19–22],
Pex8p [22] and Pex17p [18,21–23]. Although it is difficult
to imagine how a 40–60-kDa protein can interact with so
many different partners (raising the possibility that some of
the described interactions are not direct), these results do
indicate that Pex14p is a central component of the perox-
isomal import machinery. Finally, as suggested recently
[24,25], Pex14p may also be involved in the turnover of
the peroxisome.
In this work, we have investigated some of the properties
of mammalian Pex14p. Besides refining the membrane top-
ology model of this peroxin, we present evidence suggesting
that human recombinant Pex14p is able to form homopol-
ymers. These homopolymers are heterogeneous structures
and can bind in vitro synthesised [35S]Pex5p. Domain map-
ping of the Pex14p–Pex14p interaction revealed the exis-
tence of a binding domain comprising amino acid residues
147–278 of Pex14p. This portion of the protein, containing a
predicted coiled-coil motif [9,15,26], is exposed into the
cytosol.
2. Materials and methods
2.1. Protease protection assays and chemical cleavage of
proteins with CNBr
Protease protection assays were done exactly as described
previously [27].
Cyanogen bromide cleavage [28] of protease-treated
organelles was performed as follows: after inactivating
proteinase K with 500 Ag/ml phenylmethylsulfonyl fluoride
or PMSF (added from a 50 mg/ml stock solution in ethanol)
for 5 min on ice, organelle samples were diluted with 900 Al
of SEI buffer (0.25 M sucrose, 5 mM imidazole pH 7.4, 1
mM ethylenediaminetetraacetate disodium salt or EDTA/
NaHO pH 7.4) supplemented with 1:100 (v/v) mammalian
protease inhibitor cocktail (Sigma, USA) and centrifuged at
15000 g for 15 min at 4 jC. Peroxisomal pellets were then
solubilised in 5 Al of 1% (w/v) sodium dodecyl sulfate (SDS)
and subjected to CNBr cleavage by adding 40 Al of 57 mg/ml
CNBr in 79% (v/v) formic acid containing 1:100 (v/v)
protease inhibitor cocktail. Control samples received an
equal volume of 79% (v/v) formic acid only. All the samples
were incubated at room temperature for 5 h and lyophilised.
2.2. Expression of fusion proteins
The rat Pex2p cDNA encoding amino acids 1–305 was
amplified from rat liver total RNA by reverse transcription
polymerase chain reaction (RT-PCR) using the primers 5V-
CGCGAATTCATGGCTGCCAGAGAAGAGAGTACA-3V
and 5V-CGGCTGCAGTGGTTTCTAAAGAGCATT-
CACTTCTG-3V, designed according to the published
sequence [29]. The amplified cDNA fragment was digested
with EcoRI and PstI and cloned into the pBluescript II KS
vector (Stratagene, USA). This recombinant plasmid was
digested with EcoRI and NotI, and the insert obtained was
cloned into the pGEX-5X-1 expression vector (Amersham
Biosciences, USA).
The cDNA encoding amino acids 1–373 of human
Pex3p was amplified from human skin fibroblasts total
RNA by RT-PCR, using the primers 5V-CGCGTCGA-
CATGCTGAGGTCTGTATG-3V and 5V-CGCGTCGACT-
CATTTCTCCAGTTGCT-3V, designed according to the
published sequence [30]. The Pex3p cDNAwas then cloned
into the pGEMR-T Easy vector, following the manufactur-
er’s instructions (Promega, USA). This recombinant plas-
mid was digested with SalI, and the insert was cloned in
pGEX-4T-3 expression vector (Amersham Biosciences).
The amplification and cloning into the pGEMR-T Easy
vector of a cDNA encoding amino acids 1–639 of human
Pex5p was described previously [27]. This plasmid, here-
after referred to as pGEMT–Pex5p, was used as a template
in a PCR reaction using the primers 5V-GGCGTCGACTG-
GAGATCTATGGCAATGCGGGAGCTGGTGGA-3V and
5V-GGGTCTAGAGCGGCCGCGTCGACCTGTCACTGG-
GGCAGGCC-3V. This product was digested with BglII and
NotI and inserted into the BamHI and NotI sites of the
pGEX-4T-3 expression vector.
The cDNA encoding amino acids 1–247 of human
Pex11p was amplified from human skin fibroblasts total
RNA by RT-PCR, using the primers 5V-CGCGTCGACGC-
CATGGACGCCTTCACC-3V and 5V-CGCAAGCTTCC-
TAAAAACACCCTAACG-3V, designed according to the
published sequence [31]. This cDNA fragment was then
cloned into the pGEMR-T Easy vector. The recombinant
plasmid was digested with the restriction enzymes SalI and
NotI and the insert was cloned into the pGEX-4T-3 expres-
sion vector.
The human Pex19p cDNA encoding amino acids 1–299
was amplified from human kin fibroblasts total RNA by RT-
PCR, using the primers 5V-CGCGGATCCAAGATGGCC-
GCCGCTGAGGAA-3V and 5V-CGCAAGCTTGTTTCA-
CATGATCAGACACTG-3V, according to the published
sequence [32]. After cloning this cDNA fragment into the
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pGEMR-T Easy vector, the recombinant plasmid was
digested with the restriction enzymes BamHI and NotI and
the insert was cloned into the pGEX-4T-3 expression vector.
The glutathione-S-transferase–Pex14p (GST–Pex14p)
encoding plasmid was obtained as described previously
[33].
All the GST fusion proteins were expressed in the XL1-
Blue strain of Escherichia coli. GST–Pex2p, GST–Pex3p
and GST–Pex11p fusion proteins were obtained as inclusion
bodies and further purified by preparative SDS-polyacryla-
mide gel electrophoresis (SDS-PAGE). This purification
method was also applied to the insoluble pool of GST–
Pex14p. GST–Pex5p and GST–Pex19p were obtained as
soluble proteins and purified by affinity chromatography
using glutathione Sepharose 4B (Amersham Biosciences).
The soluble pool of the GST–Pex14p fusion protein was
prepared using the following procedure: pelleted E. coli cells
from 100-ml induced culture were resuspended in 2 ml of
phosphate-buffered saline (PBS), 1 mM EDTA, 5 mM di-
thiothreitol (DTT), 1:500 (v/v) mammalian protease inhib-
itor cocktail and 50 Ag/ml PMSF, and sonicated two times for
25 s (with 1-min interval on ice) using a Vibra Cell/Sonics
and Materials sonicator (model VC130). The sonicated cells
were then subjected to a clarifying spin (15000 g, 15 min,
4 jC) to remove cell debris and insoluble material. About
70% of the total GST–Pex14p fusion protein was recovered
in the supernatant.
2.3. Sedimentation analysis of recombinant human Pex14p
The soluble pool of GST–Pex14p (1 ml of the super-
natant obtained as described above) was applied on the top
of a sucrose gradient (2.2 ml of 10%, 2 ml of 15.5%, 1.8 ml
of 21%, 1.6 ml of 25%, 1.3 ml of 30% and 1 ml of 35% (w/
v) sucrose in 50 mM Tris(hydroxymethyl)aminomethane or
Tris/acetic acid pH 8.0, 0.1% (w/v) Triton X-100, 1 mM
EDTA, 1 mM DTT and 1:500 (v/v) mammalian protease
inhibitor cocktail), and centrifuged at 185000 g for 14 h at
4 jC in the TST41.14 rotor (SorvallR Instruments, USA).
Thirteen aliquots of 850 Al were collected from the bottom
of the tube. Equal portions of each fraction were then
precipitated with trichloroacetic acid and analysed by
SDS-PAGE.
In order to analyse the sedimentation properties of
Pex14p alone, GST–Pex14p present in fractions 5 and 6
of the previous gradient was first concentrated by adding a
saturated ammonium sulfate solution (pH 7.0 with NH4OH)
to 35% saturation. After 15 min on ice, the suspension was
centrifuged (15000 g for 15 min at 4 jC) and the pellet
was resuspended in 300 Al of 50 mM Tris/acetic acid pH
8.0, 0.1% (w/v) Triton X-100, 2.5 mM CaCl2, 1 mM EDTA
and 5 mM DTT. GST–Pex14p was then cleaved with 5
Units of thrombin (Sigma T4648; stock solution 5 mg of
solid/ml of 50 mM Tris/HCl pH 7.5) by incubating for 1 h at
room temperature. The protease was inactivated by adding
1:500 (v/v) mammalian protease inhibitor cocktail and
PMSF to 50 Ag/ml. Thrombin-cleaved GST–Pex14p was
then applied on the top of a sucrose density gradient as
described above.
2.4. In vitro synthesis of [35S]-labelled proteins by coupled
transcription/translation
The human Pex5p cDNA was obtained by cleaving
pGEMT–Pex5p with SalI and inserted on the SalI site of
pGEM-4 vector (Promega). This recombinant plasmid was
linearised with NheI and transcribed in vitro using T7 RNA
polymerase, according to the manufacturer’s instructions
(T7 Cap-Scribe, Roche, Germany). Radiolabelled Pex5p
was synthesised in a rabbit reticulocyte lysate in the pres-
ence of [35S]methionine, according to the manufacturer’s
protocol (Translation Kit Reticulocyte Type II, Roche).
The cDNA encoding full-length Pex14p inserted into the
pGEMR-T Easy vector [33] was extracted from this plasmid
by digestion with SalI and SphI and cloned into the pGEM-4
vector, yielding pGEM4–Pex14p. This plasmid was line-
arised with the restriction enzyme HindIII and transcribed in
vitro using SP6 RNA polymerase, according to the manu-
facturer’s protocol (SP6 Cap-Scribe, Roche). Radiolabelled
Pex14p was synthesised as described above.
Truncated forms of [35S]Pex14p were obtained using an
expression-PCR (E-PCR) strategy, as described [34]. Two
sequential PCRs were done to amplify the relevant portion
of the cDNA and to introduce a T7 RNA polymerase
promoter sequence upstream of Pex14p sequences. In the
first PCR, the pGEM4–Pex14p plasmid was subjected to
amplification using the pairs of primers listed on Table 1.
All the upper primers contained a linker sequence ‘GGGA-
GAGCCACC’ before the initiation codon; the lower pri-
mers contained three ‘ATG’ codons before the stop codon to
improve the signal in the autoradiography. The cDNA
fragments obtained in this way were then subjected to a
second PCR amplification using the respective lower pri-
mers and an upper primer (5V-GAATTCCTAATACGACT-
CACTATAGGGAGAGCCACCATG-3V) containing the T7
RNA polymerase promoter sequence followed by the linker
sequence. These DNA fragments were then subjected to in
vitro transcription/translation.
Table 1
Primers used in expression-PCR of truncated Pex14p proteins
Truncated
Pex14p proteins
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2.5. Blot-overlay assays
GST–Pex2p, GST–Pex3p, GST–Pex5p, GST–Pex11p,
GST–Pex14p and GST–Pex19p were resolved by SDS-
PAGE (1–2 Ag/lane) and blotted onto nitrocellulose mem-
branes (Schleicher & Schuell, USA). These membranes
were incubated in renaturing buffer containing 50 mM
Tris/HCl pH 7.5, 100 mM potassium acetate/acetic acid
pH 7.2, 150 mM NaCl, 1 mM DTT, 5 mM MgCl2, 1 mM
EDTA, 100 AM ZnCl2, 100 mM methionine, 0.3% (w/v)
Tween-20 and 5% (w/v) nonfat dry milk for 2 h at 4 jC, as
described [9]. Individual membranes were probed with
equal amounts (as estimated by fluorography of dried SDS
polyacrylamide gels) of the different [35S]Pex14p pro-
teins—1 to 4 Al of reticulocyte lysates in 2 ml of renaturing
buffer. Following an incubation overnight at 4 jC, the
membranes were washed two times with renaturing buffer
and dried for autoradiography.
2.6. Miscellaneous
Isolation of highly pure peroxisomes from mouse and rat
liver by differential centrifugation and Nycodenz gradient
purification was performed as described [35], with minor
modifications [33].
Alkaline extraction of organelles was done according to
Fujiki et al. [36].
Proteins were measured by the Lowry method using
bovine serum albumin as standard [37].
SDS-PAGE was performed in 1.0-mm-thick, 12% poly-
acrylamide gels using the Laemmli discontinuous buffer
system [38]. Urea–SDS polyacrylamide gels [39] were used
in some experiments as indicated in the figure legends.
Western blotting onto nitrocellulose membranes was per-
formed according to the manufacturer’s instructions (Schlei-
cher & Schuell).
The preparation and characterisation of the antibodies
against Pex5p [27], Pex14p(1–134) [26] and Pex14p [33]
were described previously. A monoclonal antibody (clone
7H10-BD4) directed to the a subunit of the mitochondrial
ATPase, a peripheral membrane protein [40], was purchased
from Molecular Probes (USA).
The molecular mass markers used to calibrate the sucrose
density gradients were bovine serum albumin (66 kDa), beef
heart lactate dehydrogenase (140 kDa) and beef liver
catalase (232 kDa).
3. Results
3.1. Characterisation of the membrane topology of
mammalian Pex14p
In a first attempt to define the membrane topology of
mammalian Pex14p, we have performed a protease protec-
tion assay. For this purpose, purified rat liver peroxisomes
were treated with increasing amounts of proteinase K. After
inactivating the protease, protein samples were analysed by
Western blotting using antibodies directed to Pex14p(1–
134) [26]. The behaviour of Pex5p was also monitored in
these experiments. As shown previously [27], peroxisomal
Pex5p is completely degraded at low proteinase K concen-
trations when the peroxisomal compartment is not intact. On
the other hand, when intact organelles are used in these
experiments, only a short fragment of approximately 2 kDa
can be clipped off from Pex5p by the action of proteinase K.
Thus, Pex5p provides the means to control both the proteo-
lytic activity of proteinase K and the intactness of the
organelles used in these experiments.
As shown in Fig. 1A, when intact peroxisomes are
treated with low concentrations of proteinase K (1–5 Ag/
ml), Pex14p is degraded to a 31-kDa fragment. A very
similar result was described recently for human Pex14p
[26]. However, this fragment is still partially protruding into
the cytosolic side of the peroxisomal membrane. Indeed, at
higher proteinase K concentration this fragment is com-
pletely degraded giving rise to a smaller fragment of 16
kDa. Increasing the protease concentration up to 0.5 mg/ml
has no further effect on the cleavage profile of Pex14p (data
not shown).
Mammalian Pex14p behaves as an intrinsic membrane
protein [9,15,26]. Considering the results presented above it
is plausible to assume that the 16 kDa Pex14p fragment
obtained after proteinase K digestion of intact peroxisomes
contains a major (if not the only) membrane association
domain. Indeed, when protease-treated intact peroxisomes
are subjected to alkaline extraction in order to separate
intrinsic membrane proteins from peripheral membrane
and soluble proteins, this 16-kDa fragment remains in the
intrinsic membrane protein fraction (Fig. 1B). Thus, at least
a small domain of the 16 kDa fragment is embedded in the
peroxisomal membrane. But does this fragment cross com-
pletely the membrane of the organelle? In an attempt to
answer this question, we performed proteinase K digestions
of peroxisomal proteins using disrupted peroxisomes. Two
different methods were used to provide access of the
protease to the lumenal domains of peroxisomal proteins,
as described before [27]: the organelles were either solubi-
lised using mild detergents before protease treatment or they
were disrupted by sonication in the presence of proteinase
K. As shown in Fig. 1A (lanes 7–8), when Triton X-100-
solubilised peroxisomes are incubated in the presence of
low concentrations of proteinase K, no immunodetectable
fragment of Pex14p can be obtained. Essentially the same
results were observed when 1% (w/v) digitonin instead of
Triton X-100 was used in these experiments (data not
shown). This result could suggest that at least a small
portion of the 16-kDa Pex14p fragment is exposed to the
lumenal side of the peroxisomal membrane. However, this
interpretation is not corroborated by the second experiment
in which peroxisomes were sonicated in the presence of
proteinase K. Under these conditions, no further cleavage of
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the 16-kDa fragment was observed. Again, as described
above, we tested higher proteinase K concentrations (0.5
mg/ml), but virtually the same result was obtained (data not
shown). Many different hypotheses can be envisaged to
explain this discrepancy (see Discussion). However, the
bottom line here is that the membrane topology of this
Pex14p fragment cannot be inferred from these experiments.
Taking into account that the anti-Pex14p antibody used
in these experiments was produced against amino acid
residues 1–134 of this peroxin, we still considered the
possibility that the 16-kDa fragment detected in the pro-
tease-protection experiments could represent a domain of
Pex14p lacking some N-terminal residues. Thus, we have
mapped the region of Pex14p corresponding to this 16-kDa
fragment. This was accomplished using the specific methio-
nine-cleavage chemical, CNBr. As shown in Fig. 2, when
CNBr-treated peroxisomal proteins from rat liver are ana-
lysed by Western-blotting using the anti-Pex14p antibody,
an 18-kDa fragment is observed (lane 3). This fragment
corresponds to amino acid residues 2–148 of rat Pex14p
(the second methionine in the rat Pex14p primary structure
appears at position 148 [15]). When intact rat liver perox-
isomes are first subjected to proteinase K in order to degrade
Pex14p to its 16-kDa fragment and afterwards treated with
CNBr, no further cleavage is observed (Fig. 2, lane 4).
There are two possibilities to explain this result: (1) protei-
nase K cleaves rat Pex14p in the neighbourhood of Met-148
and clips approximately 2 kDa from the N terminus of the
protein; or (2) proteinase K hydrolyses rat Pex14p in a
region located approximately 2 kDa before Met-148. To
clarify this point, we explored the fact that mouse Pex14p
(GenBank accession number AAF04616) has an additional
methionine at position 116. When mouse liver peroxisomal
proteins are treated with CNBr, two fragments arising from
Pex14p can be detected upon Western blot analysis using
the anti-Pex14p antibody (Fig. 2, lane 7). Clearly, CNBr
Fig. 2. The proteinase K-resistant 16-kDa fragment of Pex14p corresponds
to the N-terminal 130 amino acid residues. Forty micrograms of purified
liver peroxisomes from rat or mouse was treated with proteinase K (PK), at
the indicated concentrations. After inactivating the protease, samples were
diluted with SEI buffer and centrifuged to pellet the organelles. Peroxisomal
proteins were then subjected to CNBr cleavage in 70% (v/v) formic acid.
Control samples received the same amount of the formic acid solution.
After 5 h at room temperature, protein samples were lyophilised and
subjected to urea-SDS-PAGE. The antibody anti-Pex14p(1–134) was used
in the immunoblotting analysis. The positions of the molecular mass
markers are shown.
Fig. 1. Membrane topology of Pex14p. (A) Forty micrograms of purified rat
liver peroxisomes was incubated in the presence of different concentrations
of proteinase K (PK). After inactivation of the protease, protein samples
were precipitated with trichloroacetic acid, resolved by urea–SDS-PAGE
and analysed by immunoblotting using anti-Pex5p and anti-Pex14p(1–134)
antibodies. Organelles solubilised with Triton X-100 (TX-100) were also
subjected to protease treatment as a control. Some of the samples were
sonicated immediately after the addition of proteinase K. (B) Eighty
micrograms of purified peroxisomes was treated with proteinase K (100 Ag/
ml final concentration). After inactivating the protease, the organelles were
subjected to alkaline extraction. Half of the sample was separated into
membrane (P) and soluble (S) fractions by centrifugation. The other half
was used for determination of recoveries (T). After trichloroacetic acid
precipitation, proteins were analysed by immunoblotting using antibodies
against Pex14p(1–134) and the a subunit of mitochondrial ATPase. The
positions of the molecular mass markers are shown.
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cleavage was not complete at Met-116 of mouse Pex14p
although exactly the same conditions were used to cleave
both the rat and mouse proteins. Different cleavage effi-
ciencies of methionines in different protein contexts are a
well-documented characteristic of the CNBr chemistry [28].
Thus, the 18-kDa fragment corresponds to amino acid
residues 2–148 of mouse Pex14p; the 15-kDa fragment
observed corresponds to amino acid residues 2–116 of
mouse Pex14p. When this procedure is repeated with mouse
peroxisomes that were previously subjected to a protease
protection assay in order to degrade Pex14p to its 16-kDa
fragment (see Fig. 2, lane 6), a 15-kDa fragment is now
observed (lane 8). Thus, the 16-kDa fragment obtained after
proteinase K digestion of Pex14p still contains Met-116.
Furthermore, since a 15-kDa fragment is obtained after
CNBr cleavage in both the proteinase K digested (Fig. 2,
lane 8) and undigested (Fig. 2, lane 6) samples, this experi-
ment also implies that no significant number of N-terminal
residues are removed from Pex14p by the action of protei-
nase K (proteolytic removal of five residues or more from
the N terminus of Pex14p would have been easily detected
in the gel presented in Fig. 2). Thus, the 16-kDa Pex14p
fragment obtained after proteinase K digestion corresponds
approximately to amino acid residues 1–130.
Taken together, the data presented here indicates that the
first 130 amino acid residues of mammalian Pex14p are
highly resistant to proteinase K when the peroxisomal
membrane is intact (i.e., in the absence of detergents). Our
results also show that this domain alone displays the
characteristics of an intrinsic membrane protein. Finally,
our data also suggest that the C-terminal two thirds of
Pex14p are largely exposed into the cytosol. Evidence in
support of this conclusion comes from the experiments
presented in Figs. 1 and 3. When using intact rat liver
peroxisomes and low concentrations of proteinase K, four
Pex14p fragments can be detected (see lanes 3 and 4 of Fig.
1A). All these fragments (still containing the epitopes
recognised by the anti-Pex14p antibody) can be degraded
into the smaller 16-kDa fragment when the proteinase K
concentration is increased. Thus, they correspond to C-
terminal truncated forms of Pex14p. The same observation
can be made in a more impressive way when intact purified
rat liver peroxisomes are incubated with increasing concen-
trations of trypsin (see Fig. 3). In this case, multiple C-
terminal truncated forms of Pex14p can be observed.
3.2. Recombinant human Pex14p forms homopolymers
In a previous study we described the production of a
recombinant GST–Pex14p fusion protein with the purpose
of raising antibodies [33]. During the course of that work, it
was noticed that only a fraction of the recombinant GST–
Pex14p fusion protein was found in inclusion bodies after
overexpression in E. coli cells. Indeed, more than 70% of
the recombinant protein could be easily recovered as a
soluble protein when these cells were disrupted by mild
sonication in the presence of 0.1% (w/v) Triton X-100 (data
not shown). Similar observations regarding the solubility of
human recombinant Pex14p were made recently [17,26].
Since it has been shown that Pex14p interacts with itself
using in vitro binding assays [15] and the two-hybrid system
[19–23], we tried to explore the solubility of this recombi-
nant protein to study in more detail the Pex14p–Pex14p
interaction. The aim was to obtain data concerning the
degree of homopolymerisation of Pex14p.
We first tried to determine the molecular mass of the
GST–Pex14p protein. For this purpose, E. coli cells expres-
sing the fusion protein were gently sonicated in order to
release soluble proteins. After a clarifying spin to remove
cell debris and insoluble proteins, the supernatant was
subjected to sucrose gradient centrifugation. As shown in
Fig. 4, GST–Pex14p can be found almost over the entire
gradient—from fraction 9 (representing dimeric protein) to
fraction 1 (corresponding to a very high molecular mass). It
is important to note that no other E. coli protein presents this
kind of sedimentation profile. Thus, the observed behaviour
represents a specific property of the fusion protein alone,
implying that recombinant GST–Pex14p is a homopolymer
displaying variable stoichiometries.
Since GST itself is a dimeric protein [41], most of the
intermolecular interactions inferred from the previous
experiment could be the result of GST–GST interactions.
In order to remove this uncertainty, we cleaved the GST–
Pex14p fusion protein with thrombin (this protease cleaves
the GST moiety from the fusion protein) and reanalysed the
sedimentation behaviour of the recombinant human peroxin.
We selected for this experiment GST–Pex14p present in
fractions 5 and 6 (apparent molecular mass 250–500 kDa) of
a sucrose gradient similar to the one described above. (For
Fig. 3. The C-terminal domain of Pex14p is exposed to the cytosol. Forty
micrograms of purified rat liver peroxisomes was digested with different
amounts of trypsin, as indicated. After inactivation of the protease, protein
samples were precipitated with trichloroacetic acid, resolved by urea-SDS-
PAGE and analysed by immunoblotting using anti-Pex5p and anti-
Pex14p(1–134) antibodies. The positions of the molecular mass markers
are shown.
M.E.M. Oliveira et al. / Biochimica et Biophysica Acta 1567 (2002) 13–2218
reasons that will be explained below, 5 Ag of thrombin-
cleaved GST–Pex14p was pre-incubated with a radiochem-
ical amount of in vitro synthesised human [35S]Pex5p before
loading onto the sucrose gradient.) As shown in Fig. 5A, the
majority of human Pex14p derived from fractions 5–6 of the
first gradient are now detected in fractions 5–8 of the second
sucrose gradient. This observation has two implications:
first, GST–GST interactions are not the main driving force
for the homopolymerisation of the GST–Pex14p fusion
protein; second, Pex14p homopolymers are stable entities
under the experimental conditions used. Of relevance is also
the fact that the GST moiety of the thrombin-cleaved fusion
protein is found in fractions 10–11 of the gradient (repre-
senting monomeric/dimeric protein), suggesting that at least
the N-terminal 1/3 of the GST–Pex14p fusion protein was in
a correctly folded conformation.
As stated above, we included in the sucrose gradient
sedimentation analysis of Pex14p a radiochemical amount
of human [35S]Pex5p. The aim was to assess the conforma-
tional state of the recombinant Pex14p protein. As shown in
Fig. 5B, in the absence of Pex14p, in vitro synthesised
human [35S]Pex5p behaves as a monomeric protein (Fig.
5B, fraction 10 of the gradient). A similar result was
described recently for rat liver cytosolic Pex5p [27]. How-
ever, when [35S]Pex5p is pre-incubated with recombinant
Pex14p before the sucrose gradient centrifugation step, a
quite different result is obtained—Pex5p is now detected as
a high molecular mass complex. Thus, at least a small
fraction of the Pex14p homopolymers are able to bind
[35S]Pex5p, suggesting that the recombinant peroxin is in
a correct folded state.
3.3. Domain mapping of the Pex14p–Pex14p interaction
The primary structure of Pex14p from several organisms
reveals the existence of a coiled-coil motif in the middle
region of the peroxin [9,15,19,20,22,26]. Coiled-coil motifs
are involved in protein–protein interactions and can give
rise to dimeric, trimeric, tetrameric and, possibly, pentame-
ric structures [42]. Thus, it seems likely that this type of
interaction is involved in the homopolymerisation process
observed for human Pex14p. However, no experimental
data supporting this hypothesis were yet provided.
In an attempt to define the domain(s) involved in the
Pex14p–Pex14p interaction, we have synthesised in vitro
several truncated forms of the human Pex14p. The capacity
of these shorter versions of [35S]Pex14p in binding full-
length recombinant Pex14p was then assessed by a blot-
overlay assay. Several other recombinant peroxins were also
used as controls, namely, Pex2p, Pex3p, Pex5p, Pex11p and
Pex19p. The results of this experiment are shown in Fig. 6.
No binding to Pex2p, Pex3p or Pex11p was detected with
any of the in vitro synthesised [35S]Pex14p forms used in
this assay. In contrast, a very strong binding to Pex5p was
observed with all the [35S]Pex14p forms containing at least
amino acid residues 1–79. This result is in agreement with
the Pex5p-binding domain mapping data reported previ-
ously for human Pex14p [43]. Human Pex14p also binds
Pex19p [17]. As shown recently [17], Pex14p amino acid
residues 108–147 are necessary for the interaction with
Pex19p. Our results are compatible with these data: amino
acid residues 79–155 of Pex14p are necessary for the
interaction with Pex19p.
Fig. 5. Homopolymeric recombinant Pex14p binds Pex5p. In vitro
synthesised [35S]Pex5p was pre-incubated with (panel A) or without (panel
B) human recombinant Pex14p (obtained as described in Materials and
methods) and subjected to sedimentation analysis. The gradients were
fractionated into 12 aliquots, starting from the bottom of the tube. Equal
portions from each fraction were analysed by immunoblotting using the
anti-Pex14p and anti-GST antibodies. [35S]Pex5p was detected by
autoradiography of the dried blot. Lane T—one fifth of the samples was
loaded on the sucrose gradients. The numbers at the bottom indicate the
positions of the molecular mass markers used to calibrate the gradients.
Fig. 4. GST–Pex14p is a homopolymer of heterogeneous size. Total
soluble proteins obtained from E. coli cells expressing GST–Pex14p were
subjected to sucrose gradient centrifugation as described in Materials and
methods. The gradient was fractionated into 13 aliquots, starting from the
bottom of the tube. Equal portions from each aliquot (corresponding to 1 ml
of the initial culture) were analysed by SDS-PAGE. A Coomassie blue-
stained gel is shown. The identity of the GST–Pex14p fusion protein
(indicated on the right-hand side of the gel) was confirmed by
immunoblotting analysis (data not shown). Lane T—total soluble proteins
corresponding to 0.5 ml of the initial culture. The positions of the molecular
mass markers are shown. The numbers at the bottom indicate the positions
of the molecular mass markers used to calibrate the gradients.
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When the Pex14p–Pex14p interaction is analysed, a
specific binding to recombinant Pex14p is observed with
either the full-length version of the protein, [35S]Pex14p
(147–377), or [35S]Pex14p(140–278). Thus, amino acid
residues 147–278 are involved in the Pex14p–Pex14p
interaction. This is the region containing the coiled-coil
domain of Pex14p (amino acid residues 163–198, as pre-
dicted by the SMART program [44,45]). Interestingly, a
weak but specific interaction with recombinant Pex14p is
also detected with [35S]Pex14p(1–155), but not with the
shorter [35S]Pex14p(1–79) form. It is not clear at this
moment whether this result derives from the existence of a
second Pex14p–Pex14p binding domain or if Pex14p(1–
155) contains at its C terminus additional (unpredicted)
portions of the coiled-coil domain.
No specific interactions with any of the analysed perox-
ins were detected when [35S]Pex14p(262–377) was used in
this assay (data not shown).
4. Discussion
It is a generally accepted fact that mammalian Pex14p is
an intrinsic component of the peroxisomal membrane
[9,15,26]. However, data regarding the membrane topology
of this peroxin are scarce. In fact, there are only two studies
dealing with this problem [15,26]. In one of these studies
[15], it was concluded that both termini of rat Pex14p are
exposed into the cytosol. These results were obtained using
N- and C-terminal epitope-tagged versions of the rat peroxin
and, therefore, no conclusions regarding the membrane
topology of the remaining domains of Pex14p could be
withdrawn from those experiments. Experimental data sug-
gesting that the C terminus of human Pex14p is at least
partially exposed to the cytosol were provided in the second
study [26]—upon proteinase K treatment of intact organ-
elles, human Pex14p could be degraded to a 31-kDa frag-
ment still containing epitope(s) recognised by an anti-
Pex14p antibody directed to amino acid residues 1–134
(the antibody used in this work). Here, we present data
suggesting, first, that the domain comprising amino acids
residues 130–377 of rat Pex14p is completely exposed to
the cytosol, and second, that the first 130 amino acid
residues of rat Pex14p are highly protected from proteolytic
attack by the peroxisomal membrane itself. In spite of
several attempts, we were unable to degrade this 16-kDa
domain of Pex14p even when access to the protease was
provided through the matrix side of the peroxisomal mem-
brane. Our data suggest that this characteristic does not
derive from an intrinsic resistance of the 16-kDa peptide to
proteolysis by proteinase K. Indeed, proteolysis of this
domain could be easily accomplished when the peroxisomal
membrane was first solubilised using mild detergents. On
the other hand, we show that this N-terminal domain per se
behaves as an intrinsic membrane component. These results
do not necessarily mean that all the residues present in this
domain are embedded in the membrane. In fact, with the
exception of residues 109–127, the primary structure of
Pex14p reveals that this region is quite hydrophilic. It is
possible, however, that these hydrophilic residues are lying
so close to the membrane or other proteins that by sterical
hindrance no proteolytic cleavage can occur. Two peroxins,
Pex5p and Pex19p, have been shown to bind to this region
Fig. 6. Domain mapping of Pex14p–Pex14p interaction. (A) Schematic
representation of Pex14p and the truncated versions of it used in blot-
overlay assays. The black and hatched boxes represent the putative
transmembrane and coiled-coil domains, respectively. (B) One to two
micrograms of GST–Pex2p, GST–Pex3p, GST–Pex5p, GST–Pex11p,
GST–Pex14p (see below) and GST–Pex19p (indicated in the blots by 2, 3,
5, 11, 14 and 19, respectively) was subjected to SDS-PAGE and transferred
to nitrocellulose membranes (a Ponceau S-stained membrane is shown).
Individual membranes containing the recombinant proteins were incubated
with the following radiolabelled proteins: [35S]Pex14p, [35S]Pex14p(1–
155), [35S]Pex14p(1–79), [35S]Pex14p(147–377) and [35S]Pex14p(140–
278). The interactions were detected by autoradiography. A GST–Pex14p
preparation partially cleaved with thrombin was used in these experiments.
The protein band displaying the higher apparent molecular mass detected in
lanes ‘‘14’’ represents GST–Pex14p; the faster migrating protein band
corresponds to full-length Pex14p.
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of Pex14p (this paper and Refs. [17,43]). A hypothetical
model for such a Pex14p/Pex5p complex was previously
proposed [27]. In agreement with this interpretation, it is
noteworthy that antibodies directed to the N terminus of
Pex14p [26] or to an N-terminal tagged version of it [15] fail
to detect this peroxin upon immunofluorescence analysis of
mammalian cells when the peroxisomal membrane is left
intact.
How is the folding of this N-terminal domain? If we
assume that the data obtained with epitope-tagged versions
of Pex14p [15] reflect the topology of the endogenous
peroxin (i.e., the N terminus of Pex14p is facing the
cytosol), and that, as shown here, all the C-terminal domains
starting at approximately amino acid residue 130 are
exposed into the cytosol, then there are only two possibil-
ities: (1) the N-terminal domain comprising amino acid
residues 1–130 of mammalian Pex14p never crosses com-
pletely the peroxisomal membrane—it just associates later-
ally with the membrane—or (2) this domain crosses the
peroxisomal membrane an even number of times. Discrim-
inating between these two possibilities will surely be a
demanding task.
It is known for long that Pex14p interacts with itself [15].
However, the precise domain(s) involved in this interaction
and the degree of polymerisation (i.e., if this interaction
results in dimers, trimers, etc.) were never determined. In
this work, data concerning the first problem are provided.
Using a blot-overlay assay, we show that amino acid
residues 147–278, a domain containing a coiled-coil motif
[9,15,26], are involved in the Pex14p–Pex14p interaction.
Unfortunately, and in spite of several attempts using differ-
ent experimental conditions and analytical systems, we were
unable to assess the polymerisation degree of this peroxin—
Pex14p was always found as an heterogeneous entity, a
property that was also observed by electron microscopy
analysis of negatively stained preparations of recombinant
Pex14p (data not shown). There are many different possi-
bilities to explain this behaviour, going from nonspecific
association of coiled-coil complexes (as described recently
for human heat shock binding factor 1 [46]) to the existence
of additional Pex14p–Pex14p interaction domain(s) not
characterised in our experiments. Obviously, it could also
be argued that the recombinant Pex14p protein used in this
work is not correctly folded. Although we cannot com-
pletely exclude this possibility, several observations suggest
that this is not the case. First, misfolded proteins are mostly
insoluble. Second, we would not expect a misfolded protein
aggregate to be so efficiently cleaved by thrombin giving
rise to monomeric/dimeric GST. Finally, the Pex14p poly-
mers detected in our sedimentation analysis can form stable
complexes with in vitro synthesised Pex5p, suggesting that
the conformation of recombinant Pex14p mimics, at least
partially, the folding state of the endogenous Pex14p. Thus,
if credit is given to the properties of recombinant Pex14p,
our results raise the interesting possibility that Pex14p may
be a tethering protein bringing together, at the same site of
the peroxisomal membrane, many of the components
involved in the biogenesis/turnover of the organelle.
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